| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Labcorp Holdings Inc. (LH) has 24 insiders with recent SEC Form 4 filings, including 0 buys and 13 sells. LH is classified in the Health Care Providers & Services industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 107.2K | $27.27M | - | |
| VP | 36.5K | $9.28M | - | |
| COO | 12.7K | $3.22M | - | |
| VP | 7.9K | $2.00M | - | |
| VP | 6.7K | $1.72M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 21, 2024 | Eisenberg Glenn A | Chief Financial Officer, EVP | Sale+OE | 34,504 | $215.97 | $7,451,866.49 | -22.3% | -5.8% | +14.3% | |
| Feb 21, 2024 | Divincenzo Jonathan P. | EVP, Pres, Central Labs &Intl | Sell | 500 | $215.49 | $107,745.05 | -12.8% | -5.8% | +14.3% | |
| Feb 13, 2024 | Van Der Vaart Sandra D60 | EVP, Chief Legal Officer | Sell | 237 | $226.45 | $53,668.65 | -3.0% | -5.8% | +8.0% | |
| Feb 8, 2024 | Van Der Vaart Sandra D60 | EVP, Chief Legal Officer | Sell | 259 | $222.06 | $57,513.54 | -3.3% | -9.5% | +10.5% | |
| Feb 5, 2024 | Van Der Vaart Sandra D60 | EVP, Chief Legal Officer | Sale+OE | 193 | $220.57 | $42,570.01 | -2.5% | -8.5% | +12.3% | |
| Nov 16, 2023 | Wilkinson Peter J | SVP, Chief Accounting Officer | Sell | 1,384 | $210.71 | $291,626.79 | -39.9% | +8.2% | +11.6% | |
| Aug 8, 2023 | Anderson Kerrii B49 | Director | Sell | 5,000 | $211.57 | $1,057,832.50 | -24.7% | -2.0% | +2.6% | |
| Jun 29, 2023 | Van Der Vaart Sandra D60 | EVP, Chief Legal Officer | Sell | 212 | $240.00 | $50,880.00 | -2.7% | -0.8% | -1.5% | |
| May 19, 2023 | Kirchgraber Paul R | CEO, Covance Drug Development | Sale+OE | 4,300 | $216.91 | $932,706.98 | -24.9% | +14.3% | +13.1% | |
| May 18, 2023 | Schroeder Mark S56 | EVP, Pres Diagnostics &COO | Sale+OE | 1,500 | $216.77 | $325,155.00 | -18.3% | +15.9% | +13.4% |